A team of Singapore-based researchers has created an artificial intelligence (AI) platform capable of calculating a patient’s optimal prostate cancer drug dosage that ultimately stopped the disease’s progression in a patient, according to an Aug. 29 study published in Advanced Therapeutics.
Study lead, Dean Ho, director of the Singapore Institute for Neurotechnology (SINAPSE), and colleagues used their Curate.AI platform to identify the optimal dosage of a drug combination administered to a single patient with metastatic castration-resistant prostate cancer over the course of one year.
The initial dosage was adjusted by clinicians, and used, together with the patient’s prostate specific antigen (PSA) levels, to create a Curate.AI profile. The technique “remarkably” lowered the dose of a key drug in the combination by 50 percent, authors reported. Artificial intelligence-guided dosage resulted in the lowest PSA levels over the study period.
After CT imaging, researchers determined the disease’s progression had been stopped.
“Our clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment,” Ho said in a National University of Singapore story. “A patient's clinical profile changes over time. The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimized personalized medicine.”
Currently, multiple clinical trials are underway utilizing the AI platform’s guided combination therapy for cancer research, and patient recruitment for additional trials in Singapore has already been approved.
Ultimately, according to the release, Ho and colleagues would like to expand the application of their platform to areas such as cardiovascular medicine, diabetes management and infectious diseases.
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.